Lung Cancer

Bayer and Onyx have multiple clinical trials underway for individuals with lung cancer. For a more comprehensive list of Nexavar® (sorafenib) clinical trials, please visit clinicaltrials.gov or call 866-639-2827.

Phase 3 Study of Single Agent Nexavar - MISSION
Enrollment Complete
Study Design: Randomized, double-blind placebo-controlled trial
Patients: Patients with advanced relapsed or refractory predominantly non-squamous non-small cell lung cancer (NSCLC) after two or three previous treatment regimens
Purpose: To determine the effectiveness of Nexavar plus best supportive care when compared to best supportive care alone by assessing the difference in overall survival (OS), as well as to evaluate other measures of efficacy and safety
Location: Multiple centers throughout North America, South America, Europe and the Asia-Pacific region

Stock Quote (update every 15 minutes): As of 4:00pm - 5/20/2011

  • Symbol
    ONXX
  • Last
    43.71 +0.22
  • Open
    43.46
  • High
    43.81
  • Low
    42.49
  • Volume
    1139204